Kymera Therapeutics Inc, a biotechnology company, has signed a multi-program strategic collaboration with Sanofi (NASDAQ: SNY), a France-based pharmaceutical company, for developing and commercialising first-in-class protein degrader therapies targeting IRAK4, a key protein involved in inflammation, in patients with immune-inflammatory diseases, it was reported on Thursday.
Both firms will also collaborate on a second earlier stage program.
According to the terms of the deal, Sanofi will make an upfront payment of USD150m in cash to Kymera for global rights to develop IRAK4 protein degraders for inflammation and immunology indications, and a second earlier stage undisclosed program. Kymera is to advance the IRAK4 program via Phase one clinical trials and Sanofi will assume clinical development and commercialisation responsibilities thereafter. Sanofi is to lead all clinical development activities for the second program, while Kymera will have the option to participate in the development of both programs in the United States during clinical development. Kymera is to retain global rights to its IRAK4 program in oncology indications.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886